BeyondSpring Inc. (BYSI)
NASDAQ: BYSI ยท Real-Time Price ยท USD
0.3300
-0.1070 (-24.49%)
Nov 20, 2026, 4:00 PM EST - Market closed
BeyondSpring Earnings Call Transcripts
Fiscal Year 2026
-
FDA granted Fast Track designation to plinabulin plus docetaxel for post-ICI non-squamous NSCLC, enabling expedited development. DUBLIN-4 phase III will enroll 442 patients globally, with interim analysis expected in 2028. Strategic transactions improve efficiency and reduce costs.